Clavis and Clovis Sign Licensing Deal for Cancer Drug

Start-up biotech Clovis Oncology has signed a $380 million deal to license an experimental pancreatic cancer drug from Norwegian company Clavis Pharma. This marks the first licensing deal that Boulder, Colo.-based Clovis has inked. Clovis has agreed to pay Clavis $15 million up front for the drug CP-4126, a...

Cancer Vaccines: Investing Opportunities Beyond Dendreon

By Mike Havrilla, ProActive Newsroom Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space such as Cell Genesys, Favrille, and Genitope; recent advancements and study results are encouraging while Dendreon (NASDAQ: DNDN) awaits a...

[Company Profile] Ivivi Technologies

With more than 50 million surgeries taking place in the U.S. each year, many Americans face a long and painful path to recovery. The healing process is often complicated by pain-reducing treatments (such as Percocet or its generic alternatives) that produce both uncomfortable and  dangerous side effects. ...

Join Us at the 3rd Annual OneMedPlace Finance Forum

Over 100 companies and 500 investors are expected to attend the 2010 OneMedPlace Finance Forum, to take place from January 12-14 in San Francisco. The 3rd annual conference will connect emerging healthcare and life science companies with investors and strategic partners. The OneMedForum will run parallel...

CytRx to Initiate Clinical Trial for Soft Tissue Cancer Drug

CytRx, a biopharmaceutical research and development company, has announced plans to initiate a Phase II clinical trial for its drug candidate INNO-206 to treat patients who suffer from advanced, treatment-resistant soft tissue sarcomas.  Soft tissue sarcomas are cancers that form in the soft tissues of the...

ImmunoGen Signs 2nd Licensing Deal with Amgen

ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million. The deal gives biotechnology company Amgen the right to use ImmunoGen’s maytansinoid targeted antibody payload (TAP) technology to create cancer-fighting therapies to an undisclosed target. In addition to...

[Company Profile] Pico-Tesla Magnetic Therapies

Pico-Tesla Magnetic Therapies, an emerging medical technology company based in Littleton, CO, has commenced a pilot study of its Magneceutical™ Therapy as a treatment for type 2 diabetes, the most common form of the disease. The randomized, double-blind, placebo-controlled study will explore whether the...

Echo Therapeutics: Positive Developments for Needle-Free Monitoring System

By Mike Havrilla, ProActive Newsroom Echo Therapeutics (OTC: ECTE.OB) is a diabetes management company developing the needle-free Symphony Transdermal Continuous Glucose Monitoring (tCGM) System as a non-invasive, wireless, transdermal solution for monitoring blood sugar levels and the needle-free Prelude...